A5003366137- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Hematopoietic Stem Cell Transplantation
- Neutropenia and Cancer Infections
- Chronic Myeloid Leukemia Treatments
- Childhood Cancer Survivors' Quality of Life
- Retinoids in leukemia and cellular processes
- Blood disorders and treatments
- Histone Deacetylase Inhibitors Research
- Chronic Lymphocytic Leukemia Research
- Multiple Myeloma Research and Treatments
- Hematological disorders and diagnostics
- Protein Degradation and Inhibitors
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Neuroblastoma Research and Treatments
- Glioma Diagnosis and Treatment
- Pharmaceutical studies and practices
- Cancer therapeutics and mechanisms
- Medical and Health Sciences Research
- Ethics and Legal Issues in Pediatric Healthcare
- Lymphoma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Bone and Joint Diseases
- Drug Transport and Resistance Mechanisms
- Immunodeficiency and Autoimmune Disorders
Medizinische Hochschule Hannover
2015-2025
Universidade Santa Úrsula
2017
Goethe University Frankfurt
2006-2016
Hospital for Sick Children
2016
Royal Hospital for Children
2015
Newcastle University
2015
Boston Children's Hospital
1990-2015
University Hospital Münster
2004-2014
University of Münster
2002-2011
Zentrum für Kinderheilkunde
1996-2011
In pediatric relapsed acute myeloid leukemia (AML), optimal reinduction therapy is unknown. Studies suggest that liposomal daunorubicin (DNX; DaunoXome; Galen, Craigavon, United Kingdom) effective and less cardiotoxic, which important in this setting. These considerations led to a randomized phase III study by the International Berlin-Frankfurt-Münster Study Group.Patients with or primary refractory non-French-American-British type M3 AML who were younger than 21 years of age eligible....
Overall survival (OS) of pediatric patients with acute myeloid leukemia (AML) increased in recent decades. However, it remained unknown whether advances first-line treatment, supportive care, or second-line therapy mainly contributed to this improvement. Here, we retrospectively analyzed outcome and clinical data 1940 AML (younger than 18 years age), enrolled the population-based AML-BFM trials between 1987 2012. While 5-year probability OS (pOS) from 49 ± 3% (1987–1992) 76 4% (2010–2012; p...
The rates of early death (ED) and treatment-related mortality (TRM) are unacceptably high in children undergoing intensive chemotherapy for acute myeloid leukemia (AML). Better strategies supportive care might help to improve overall survival these children.In a retrospective study, we analyzed incidence, clinical features, risk factors lethal complications 901 enrolled onto the multicenter trials Acute Myeloid Leukemia-Berlin-Frankfurt-Muenster (AML-BFM) 93 AML-BFM 98.One hundred four...
Because cytogenetic data are essential for risk stratification of childhood acute myeloid leukemia (AML), the impact chromosomal aberrations is crucial.Data a large group patients younger than 18 years treated according to study AML-Berlin-Frankfurt-Münster (BFM) 98 (n = 454), including their cytogenetics, were analyzed.The favorable outcome in subgroups with t(8;21), inv(16), and t(15;17), an overall survival 91% (SE, 4%), 92% 6%), 87% 5%), respectively, was confirmed. Within this group,...
PURPOSE: To improve outcome in high-risk patients, high-dose cytarabine and mitoxantrone (HAM) was introduced into the treatment of children with acute myelogenous leukemia (AML) study AML-BFM 93. Patients were randomized to HAM as either second or third therapy block, for purpose evaluation efficacy toxicity. PATIENTS AND METHODS: A total 471 de novo AML entered onto trial; 161 at standard risk 310 high risk. After induction (daunorubicin v idarubicin), further therapy, exception HAM,...
To improve prognosis in children with acute myeloid leukemia (AML) by randomized comparisons of (1) two short consolidation cycles versus the Berlin-Frankfurt-Muenster (BFM) -type biphasic 6-week and (2) prophylactic administration granulocyte colony-stimulating factor (G-CSF) no G-CSF. Further, therapy for standard risk patients was intensified addition a second induction, HAM (high-dose cytarabine mitoxantrone).Four hundred seventy-three younger than 18 years de novo AML were enrolled...
Background Several studies of pediatric acute myeloid leukemia have described the various type-I or type-II aberrations and their relationship with clinical outcome. However, there has been no recent comprehensive overview these genetic in one large cohort.Design Methods We studied different aberrations, associations impact on prognosis a series (n=506). Karyotypes were studied, hotspot regions NPM1, CEPBA, MLL, WT1, FLT3, N-RAS, K-RAS, PTPN11 KIT screened for mutations available samples....
BACKGROUND To obtain better insight into the biology of acute myeloid leukemia (AML) in various age groups, this study focused on genetic changes occurring during a lifetime. METHODS This analyzed relation between and genetics from birth to 100 years 5564 patients with de novo AML diagnosed 1998 2012 (1192 nationwide pediatric studies [AML Berlin‐Frankfurt‐Münster 98 2004] 4372 adults registered Munich Leukemia Laboratory). RESULTS The frequencies cytogenetic subgroups were age‐dependent....